8-K
IQVIA HOLDINGS INC. (IQV)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________
FORM 8-K
______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 14, 2022 (March 10, 2022)
______________
IQVIA HOLDINGS INC.
(Exact name of registrant as specified in its charter)
______________
| Delaware | 001-35907 | 27-1341991 |
|---|---|---|
| (State or other jurisdiction<br>of incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |
4820 Emperor Blvd.
Durham, North Carolina 27703
(Address of principal executive offices)
Registrant’s telephone number, including area code: (919) 998-2000
Not Applicable
(Former name or former address, if changed since last report.)
______________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:Title of Each ClassTrading SymbolName of Each Exchange on which RegisteredCommon Stock, par value $0.01 per share“IQV”New York Stock Exchange LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging growth company | ☐ |
|---|---|
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 14, 2022, IQVIA Holdings Inc. (the “Company”) announced the appointment of Costa Panagos as President of its Research & Development Solutions (“R&DS”) business unit, effective April 1, 2022. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research organizations. Mr. Panagos joined the company in 1999 and has held numerous sales, operational and executive leadership positions across the Company. Mr. Panagos currently serves as President, Research & Development Operations, where he is responsible for the global delivery of all clinical trials, including traditional full-service trials, decentralized clinical trials and flexible staffing arrangements. Prior to his current role, Mr. Panagos served as chief executive officer of Q2 Solutions, the Company’s global clinical trial laboratory business. Before joining the Company, Mr. Panagos held various roles in the pharmaceutical division of Bayer. Mr. Panagos earned a bachelor’s degree in Biology from Brown University and an MBA from the University of Chicago Booth School of Business.
On this same date, the Company announced that Richard Staub III, President, R&DS, will retire from his current role effective April 1, 2022 but will remain with the Company as a senior advisor to the Chief Executive Officer (the “CEO”) to play an important role in business development efforts, serve on customer governance boards, and ensure a smooth transition. In Mr. Staub’s role as Senior Advisor to the CEO, he will receive compensation commensurate with this new role.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
|---|---|
| 99.1 | Press release dated March 14, 2022 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 14, 2022
| IQVIA HOLDINGS INC. | |
|---|---|
| By: | /s/ Eric M. Sherbet |
| Eric M. Sherbet | |
| Executive Vice President, General Counsel and Secretary |
Document
Exhibit 99.1
NEWS
Contact: Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com) +1.973.316.3828
Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732
IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)
RESEARCH TRIANGLE PARK, N.C. – March 14, 2022 – IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities.
Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizations. He joined the company in 1999 and has held numerous sales, operational and executive leadership positions across the company. Panagos currently serves as president, Research & Development Operations where he is responsible for the global delivery of all clinical trials, including traditional full-service trials, decentralized clinical trials and flexible staffing arrangements.
Prior to his current role, Panagos served as CEO of Q2 Solutions, IQVIA’s global clinical trial laboratory business. Before IQVIA, Panagos held various roles in the pharmaceutical division of Bayer. He earned a bachelor’s degree in Biology from Brown University and an MBA from the University of Chicago Booth School of Business.
“Costa is an experienced executive with a strong operational focus and is widely respected within IQVIA and across the industry. This has been the succession plan for a long time, and it will be a quick and seamless transition,” said Ari Bousbib, Chairman and CEO of IQVIA. “I would like to thank Richard for his leadership and extraordinary contributions to our business during his tenure. Richard will continue to play an important role in business development efforts, serve on customer governance boards, and ensure a smooth transition,” Bousbib added.
Mr. Panagos’ appointment will be effective from April 1, 2022.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and
extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 79,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.